AbbVie to Present at the Jefferies 2016 Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
CHMP Issues Positive Opinion on AbbVie's (ABBV) HUMIRA as non-Infectious Uveitis Treatment
May 27, 2016 7:09 AM EDTAbbVie (NYSE: ABBV) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for HUMIRA (adalimumab) for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids or in whom corticosteroid treatment is inappropriate. HUMIRA can also decrease corticosteroid use in corticosteroid-dependent patients.
Non-infectious uveitis is a group of diseases characterized by inflammation of the uvea, the middle layer of the eye.1 It can lead to reduced vision or vision loss and is... More
